


Stabilis



Idarubicin hydrochloride



Noms commerciaux

Idacrybin	Mexique
Idamen	Turquie
Idamycin	Canada, Etats Unis d'Amérique, Mexique
Idaralem	Colombie, Mexique
Ondarubin	Mexique
Rubix	Mexique
Zavedos	Afrique du sud, Allemagne, Arabie Saoudite, Argentine, Australie, Autriche, Belgique, Chili, Colombie, Croatie, Danemark, Equateur, Espagne, Finlande, France, Grande Bretagne, Grèce, Hongrie, Irlande, Islande, Italie, Luxembourg, Malaisie, Maroc, Norvège, Nouvelle Zélande, Pays bas, Pologne, Portugal, Roumanie, Russie, Slovénie, Suède, Suisse, Thaïlande, Vénézuéla



Stabilité des solutions

PP	RL	[]	- +	☀️	⌚	⚖️	⚠️	📖
PP	RL	0,1 mg/ml	25°C	☀️	28	☾		632
PP	RL	0,1 mg/ml	25°C	☀️	28	☾		632
PP	RL	4 mg/ml	2-8°C	☀️	7	☾		4661







Facteur influençant la stabilité







☾	NaH CO3	➔	🧪	491
---	---------	---	---	-----



Compatibilités

			
			3595
			491
			307
			3
			491
			491
			99
			491
			491
			491
			1496
			1496
			3526
			491
			491
			491
			491
			491
			491
			491
			491
			491
			1410
			244

		Idarubicin hydrochloride Fluorouracil		3474
		Idarubicin hydrochloride : 1 mg/ml Furosemide : 0,8 & 10 mg/ml		491
		Idarubicin hydrochloride : 0.5 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Idarubicin hydrochloride : 1 mg/ml Gentamicin sulfate : 3 mg/ml		491
		Idarubicin hydrochloride : 0.5 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Idarubicin hydrochloride : 1 mg/ml Heparin sodium : 100 & 1000 UI/ml		491
		Idarubicin hydrochloride : 1 mg/ml Hydrocortisone sodium succinate : 2 & 50 mg/ml		491
		Idarubicin hydrochloride : 1 mg/ml Imipenem - cilastatin sodium : 5 mg/ml		491
		Idarubicin hydrochloride : 1 mg/ml Lorazepam : 2 mg/ml		491
		Idarubicin hydrochloride : 1 mg/ml Mannitol : 12.5 mg/ml		491
		Idarubicin hydrochloride : 1 mg/ml		491
		Idarubicin hydrochloride : 1 mg/ml Magnesium sulfate : 2 mg/ml		491
		Idarubicin hydrochloride : 0.5 mg/ml Melphalan : 0.1 mg/ml		169
		Idarubicin hydrochloride : 1 mg/ml Methotrexate sodium : 25 mg/ml		491
		Idarubicin hydrochloride Methotrexate sodium		3637
		Idarubicin hydrochloride : 1 mg/ml Metoclopramide hydrochloride : 5 mg/ml		491
		Idarubicin hydrochloride : 1 mg/ml Pethidine hydrochloride : 1 & 50 mg/ml		491
		Idarubicin hydrochloride : 0.5 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
		Idarubicin hydrochloride : 1 mg/ml Potassium chloride : 30 mEq/l		491
		Idarubicin hydrochloride : 1 mg/ml Ranitidine hydrochloride : 1 mg/ml		491
		Idarubicin hydrochloride : 0.5 mg/ml Sargramostim : 10 µg/ml		335
		Idarubicin hydrochloride : 1 mg/ml Sodium bicarbonate : 7.56 mg/ml		491
		Idarubicin hydrochloride : 0.5 mg/ml Teniposide : 0.1 mg/ml		905
		Idarubicin hydrochloride : 0.5 mg/ml Thiotepa : 1 mg/ml		249
		Idarubicin hydrochloride : 1 mg/ml Vancomycin hydrochloride : 4 mg/ml		491
		Idarubicin hydrochloride : 1 mg/ml Vincristine sulfate : 1 mg/ml		491

		Idarubicin hydrochloride : 0.5 mg/ml Vinorelbine tartrate : 1 mg/ml		84
		Idarubicin hydrochloride		491



Voie d'administration



Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
491	Revue	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.

632	Revue	Beijnen JH, Rosing H, De Vries PA, Underberg WJM. Stability of anthracycline antitumour agents in infusion fluids. J Parenter Sci Technol 1985 ; 39: 220-222.
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1496	Revue	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
3474	Laboratoire	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3526	Laboratoire	Clindamycin (Dalacin®) - Summary of Product Characteristics Pharmacia 2010
3595	Laboratoire	Aciclovir - Summary of Product Characteristics Hospira 2009
3637	Laboratoire	Methotrexate (Methotrexate solution for injection®) - Summary of Product Characteristics Hameln Pharmaceuticals 2014
4661	Revue	Bourcier B, Lagarce R, Lebreton V. Stability of a high-concentrated aqueous solution of idarubicin stored in a polypropylene syringe for transarterial chemoembolization J Pharm Biomed Anal 2022



Dictionnaire

 Anticancéreux	 Injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Polypropylène
 NaCl 0,9% ou glucose 5%	 A l'abri de la lumière
 Jour	RL Ringer lactate
 Seringue polypropylène	 Eau pour préparation injectable
 Facteur influençant la stabilité	 Solvant
 NaHCO ₃	 Provoque
 Dégradation	 Compatibilités
 Molécule	 Incompatibilité non précisée
 Incompatible	 Turbidité immédiate
 Chlorure de sodium 0,9%	 Précipitation en 1 heure
 Compatible	 Glucose 5%
 Turbidité en 1 heure	 NaCl 0,9% + bactériostatique
 Précipitation immédiate	 Dégagement gazeux
 Changement de couleur	 Précipitation en 24 heures
 Nutrition parentérale (mélange binaire)	 Voie d'administration
 Intraveineuse	 Bibliographie
 Dictionnaire	